[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fibromuscular-dysplasia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fibromuscular-dysplasia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,72,97,132,236,258],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100206702","defining-the-basis-of-fibromuscular-dysplasia-fmd-100206702",false,"NCT01967511","Defining the Basis of Fibromuscular Dysplasia (FMD)","Defining the Basis of Fibromuscular Dysplasia: The Define-FMD Study","DEFINE","Inclusion Criteria:\n\n* Patients of any age and freely willing to participate. For patients \\\u003C 18 years of age consent will be via parents.\n* Fluency in either English or Spanish.\n* Signed, informed consent\n* For FMD, SCAD or CvAD subjects - a clinical diagnosis of FMD, SCAD or CvAD with fulfillment of standard diagnostic criteria.\n* For healthy controls - no clinical features of FMD, SCAD or CvAD and absence of any major ongoing systemic disease including any condition requiring hospitalization, immune suppression, intravenous or injected medications or that result in functional impairment in the performance of activities of daily living. Healthy controls will be matched to enrolled FMD patients on the basis of gender and approximate age (within a 5 year window of another FMD subject).\n\nExclusion Criteria:\n\n* Patients who have co-morbidities which reduces life expectancy to one year.\n* Patients with any solid organ or hematological transplantation, or those in whom transplantation is considered.\n* Active autoimmune disease.\n* Illicit drug use.\n* HIV positive.\n* Prior malignancy.\n* Any other form of vascular disease, including other arteriopathy coronary artery disease or peripheral vascular disease\n* Family history of arteriopathy other than FMD, SCAD or CvAD (e.g. Ehlers-Danlos syndrome)",true,"ALL","18 Years",{"count":21,"type":22},600,"ESTIMATED","OBSERVATIONAL","The purpose of this study has evolved and expanded since its inception. Originally the intent was to establish the functional, molecular and genetic profile of fibroblasts from Fibromuscular Dysplasia (FMD) patients as compared to carefully matched control subjects. While this remains among the objectives, the study has been expanded to undertake a fully powered cross-tissue systems genetics analysis of FMD, and now also the related arteriopathies spontaneous coronary artery dissection (SCAD) and cervical artery dissection (CvAD). The overall objective is to disclose the core biologic mechanisms of these disorders.",[26,27,28],"Fibromuscular Dysplasia","Spontaneous Coronary Artery Dissection","Cervical Artery Dissection",[30,31,32,27,28],"Cross-sectional study","Fibromuscular dysplasia","Fibroblast","RECRUITING","2026-06-22",{"date":36,"type":37},"2026-06-24","ACTUAL",{"date":39,"type":37},"2013-10-01",{"date":41,"type":22},"2030-12",{"name":43,"class":44},"Icahn School of Medicine at Mount Sinai","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":68,"leadSponsor":70,"locationsCount":45},"100633669","survey-on-physical-activity-and-qualify-of-life-in-fibromuscular-dysplasia-100633669","NCT07529691","Survey on Physical Activity and Qualify of Life in Fibromuscular Dysplasia","National Survey of Physical Activity Restrictions and Quality of Life Among Patients With Fibromuscular Dysplasia","Inclusion criteria:\n\n* Participants with a diagnosis of fibromuscular dysplasia\n* Age range = 18-100 years\n\nExclusion Criteria:\n\n* Subjects who have an inability to complete the electronic consent form or electronic survey for any reason\n* Subjects who are non-English speaking who cannot read the electronic consent form or electronic survey","100 Years",{"count":55,"type":22},2000,"Fibromuscular dysplasia (FMD) is a disease of the arteries that is not due to plaque build-up or inflammation. While some patients with FMD are health, some may experience heart attacks, strokes, aneurysms or blood vessel dissection\u002Ftearing which can be life-threatening. It predominantly impacts women and younger patients. As a result of this diagnosis, many patients are counseled to restrict or avoid certain physical activities out of concern for provoking or worsening vascular complications. There are no guidelines or consensus recommendations regarding appropriate physical activity for patients with FMD. The lack of consensus may lead to confusion for patients and may negatively impact their quality of life. This study will conduct a large, national survey of patients with FMD to assess the type of physical activity restrictions and impact on quality of life and emotional well-being.",[58,26,27],"Fibromuscular Dysplasia of Arteries",[60,31,61,62,63],"FMD","SCAD","Exercise","Quality of life","2026-04-14",{"date":66,"type":37},"2026-04-20",{"date":64,"type":37},{"date":69,"type":22},"2027-06-30",{"name":71,"class":44},"Vanderbilt University Medical Center",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":18,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":45},"100633444","a-study-of-exercise-in-patients-with-spontaneous-coronary-artery-dissection-and-fibromuscular-dysplasia-100633444","NCT07526766","A Study Of Exercise In Patients With Spontaneous Coronary Artery Dissection And Fibromuscular Dysplasia","Cardiopulmonary, Hemodynamic, And Symptom Responses To Aerobic And Resistance Exercise In Patients With Spontaneous Coronary Artery Dissection And Fibromuscular Dysplasia: A Single-center, Single-arm Prospective Clinical Trial.","Inclusion criteria:\n\n* History of Spontaneous Coronary Artery Dissection (SCAD) and\u002For Fibromuscular Dysplasia (FMD), ≥2 months post-event, and free from chest pain.\n* Able to provide written informed consent\n\nExclusion criteria:\n\n* Individuals who are clinically obese (BMI ≥36) and\u002For who suffer from musculoskeletal or other conditions that would limit exercise participation.\n* Individuals who are deemed medically unstable\n* Participants who are unable to comply with study requirements.\n* Pregnancy","21 Years","65 Years",{"count":82,"type":22},28,"INTERVENTIONAL",[85],"NA","The purpose of this study is to assess the cardiopulmonary, hemodynamic, and symptom responses to acute bouts of varying intensity aerobic and resistance exercise in people with Spontaneous Coronary Artery Dissection (SCAD) and\u002For Fibromuscular Dysplasia (FMD).",[26,27],"2026-04-06",{"date":90,"type":37},"2026-04-13",{"date":92,"type":22},"2026-04-01",{"date":94,"type":22},"2027-07-01",{"name":96,"class":44},"Mayo Clinic",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":45},"100487581","vascular-lab-resource-vlr-biorepository-100487581","NCT05628948","Vascular Lab Resource (VLR) Biorepository","Vascular Lab Resource (VLR) Biorepository Study","Inclusion Criteria:\n\n1. 18 years or older\n2. Subjects capable of providing informed consent document\n3. Subjects with diagnosed with or at risk for cardiovascular and metabolic diseases\n\nExclusion Criteria:\n\n1. Known life expectancy of ≤ 6 months at the time of enrollment\n2. Known current pregnancy\n3. Severe Anemia (last documented hemoglobin \\\u003C 7.0 g\u002FdL)",{"count":105,"type":22},500,"This is a study of biomarkers obtained from prospectively collected subject samples and their correlation with cardiovascular and metabolic diseases. The purpose of this initiative is to develop an enduring tool to allow for collaborative research between clinicians at Cleveland Clinic Main Campus and basic scientists at the Lerner Research Institute. This collaboration will allow resources to be available to clinical and basic researchers alike. This tool will enable research of vascular disease in the Vascular Lab and will leverage this valuable asset to the fullest extent to allow for interdepartmental collaboration.",[108,109,110,111,112,113,114,115,116,117,118,26,119,120,121,122],"Cardiovascular Diseases","Metabolic Disease","Peripheral Artery Disease","Carotid Disease","Aneurysmal Disease","Venous Disease","Thrombosis","Lymphedema","Lipedema","Non-Atherosclerotic Chronic Arterial Occlusive Disease","Vasculitis","Arterial Dissection","May-Thurner Syndrome","Thoracic Outlet Syndrome","Vasospasm","2025-12-15",{"date":125,"type":37},"2025-12-19",{"date":127,"type":37},"2019-11-14",{"date":129,"type":22},"2031-06-30",{"name":131,"class":44},"The Cleveland Clinic",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":140,"targetDuration":142,"studyType":23,"phases":4,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":45},"100521150","national-registry-of-rare-kidney-diseases-100521150","NCT06065852","National Registry of Rare Kidney Diseases","National Registry of Rare Kidney Diseases (RaDaR)","RaDaR","* Kidney Rare Disease\n* Paeds and adults\n* Eligibility differs for each rare disease group\n* See: https:\u002F\u002Fukkidney.org\u002Frare-renal\u002Frecruitment",{"count":141,"type":22},35000,"30 Years","The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.\n\nThe purpose of this research is to:\n\n* Develop Clinical Guidelines for specific rare kidney diseases. These are written recommendations on how to diagnose and treat a medical condition.\n* Audit treatments and outcomes. An audit makes checks to see if what should be done is being done and asks if it could be done better.\n* Further the development of future treatments.\n\nParticipants will be invited to participate on clinical trials and other studies. The registry has the capacity to feedback relevant information to patients and in conjunction with Patient Knows Best (Home - Patients Know Best), allows patients to provide information themselves, including their own reported quality of life and outcome measures.",[145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,26,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,118],"Adenine Phosphoribosyltransferase Deficiency","AH Amyloidosis","AHL Amyloidosis","AL Amyloidosis","Alport Syndrome","Atypical Hemolytic Uremic Syndrome","Autoimmune Distal Renal Tubular Acidosis","Autosomal Recessive Proximal Renal Tubular Acidosis","Autosomal Recessive Distal Renal Tubular Acidosis","Autosomal Dominant Polycystic Kidney Disease","Autosomal Recessive Polycystic Kidney Disease","Bartter Syndrome","BK Nephropathy","C3 Glomerulopathy With Monoclonal Gammopathy","C3 Glomerulopathy","Calciphylaxis","Crystalglobulinaemia","Crystal-storing Histiocytosis","Cystinosis","Cystinuria","Dense Deposit Disease","Dent Disease","Denys-Drash Syndrome","Dominant Hypophosphataemia With Nephrolithiasis and\u002For Osteoporosis","Drug Induced Fanconi Syndrome","Drug-Induced Hypomagnesemia","Drug-Induced Nephrogenic Diabetes Insipidus","Epilepsy, Ataxia, Sensorineural Deafness and Tubulopathy","Fabry Disease","Familial Hypomagnesemia With Hypercalciuria and Nephrocalcinosis","Familial Primary Hypomagnesemia With Hypocalcuria","Familial Primary Hypomagnesaemia With Normocalciuria","Familial Renal Glucosuria","Fanconi Renotubular Syndrome 1","Fanconi Renotubular Syndrome 2","Fanconi Renotubular Syndrome 3","Fibrillary Glomerulonephritis","Focal Segmental Glomerulosclerosis","Generalised Pseudohypoaldosteronism Type 1","Gitelman Syndrome","Heavy-Metal-Induced Fanconi Syndrome","Hepatocyte Nuclear Factor 1-Beta-Associated Monogenic Diabetes","Hereditary Renal Hypouricemia","Hereditary Hypophosphatemic Rickets With Hypercalciuria","Hyperuricaemic Nephropathy","IgA Nephropathy","Immunotactoid Glomerulonephritis With Organised Microtubular Mononoclonal Immunoglobulin Deposits","Inherited Renal Cancer Syndromes","Intracapillary Monoclonal IgM Without Cryoglobulin","Intraglomerular\u002FCapillary Lymphoma\u002FLeukaemia","Isolated Autosomal Dominant Hypomagnesaemia Glaudemans Type","Liddle Syndrome","Light Chain Cast Nephropathy","Light Chain Proximal Tubulopathy Without Crystals","Light Chain Proximal Tubulopathy With Crystals","Lowe Syndrome","Membranous Nephropathy","Membranoproliferative Glomerulonephritis","Medullary Cystic Kidney Disease","Minimal Change Nephropathy","Mitochondrial Disease Of The Kidney","Monoclonal Immunoglobulin Deposition Disease","Nail Patella Syndrome","Nephrogenic Diabetes Insipidus","Nephrogenic Syndrome of Inappropriate Antidiuresis","Nephronophthisis","Primary Hypomagnesemia With Secondary Hypocalcemia","Primary Hyperoxaluria","Proliferative Glomerulonephritis With Monoclonal IgG Deposits","Proximal Tubulopathy Without Crystals","Pseudohypoaldosteronism Type 1, 2A-2E","Pure Red Cell Aplasia","Retroperitoneal Fibrosis","Sickle Cell Nephropathy","Shiga Toxin Associated Haemolytic Uraemic Syndrome","Steroid Resistant Nephrotic Syndrome","Steroid-Sensitive Nephrotic Syndrome","Thin Basement Membrane Nephropathy","Thrombotic Microangiopathy With Monoclonal Gammopathy","Type 1 Cryoglobulinaemic Glomerulonephritis","Tuberous Sclerosis","Unclassified Monoclonal Gammopathy Of Renal Significance","2023-09-26",{"date":229,"type":37},"2023-10-04",{"date":231,"type":37},"2009-11-06",{"date":233,"type":22},"2039-12-31",{"name":235,"class":44},"UK Kidney Association",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":83,"phases":246,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":45},"100424268","europeaninternational-fmd-registry-and-initiative-100424268","NCT04804683","European\u002FInternational FMD Registry and Initiative","The European\u002FInternational FMD Registry and Initiative (FEIRI), a Prospective Study","FEIRI","Inclusion Criteria:\n\n(i) Patients with established FMD, i.e at least one string-of-beads (multifocal FMD) or focal stenosis (focal FMD).\n\n(ii) Patients with Spontaneous Coronary Artery Dissection (SCAD) in whom at least one lesion of multifocal FMD (string-of beads) in extra-coronary arteries has been identified (\"SCAD-FMD\").\n\n(iii) Patients with so-called \"atypical FMD\" or \"FMD-like presentation\", i.e. patients presenting with at least one dissection or 2 aneurysms \\\u003C 60-year-old, in the absence string-of-beads, focal stenosis or evidence of inherited arteriopathy.\n\nExclusion Criteria:\n\nDiagnosis based only on ultrasound (need for computed tomographic angiography , magnetic resonance angiography or catheter-based angiography to confirm the diagnosis)",{"count":245,"type":22},5000,[85],"The main objectives of FEIRI are:\n\n(i) To describe the demographic and arterial characteristics of FMD and related diseases at a global scale and according to countries and\u002For ethnic origin\n\n(ii) To evaluate the incidence and predictors of novel FMD lesions and complications\n\n(iii) To explore the commonalities and differences between FMD, SCAD and so-called atypical FMD (patients with multiple dissections and\u002For aneurysms without string-of-beads, focal stenosis or evidence of inherited arteriopathy)\n\n(iv) To contribute to the unravelling of genetic, proteomic and molecular mechanisms underlying FMD and related diseases\n\nParticipation to the FEIRI study implies:\n\n(i) Collection of demographic and standard-of-care clinical data, both retrospectively (from the diagnosis of FMD to signature of the informed consent) and prospectively (on the occasion of standard-of-care follow-up).\n\n(ii) Optional participation to a biobank implying collection of blood, urine and, in rare cases of intervention, tissue samples for genomic and proteomic analysis and identification of diagnostic and prognostic biomarkers of FMD.\n\nParticipants will be enrolled in centres from over 20 countries in Europe and beyond.",[26],"2022-05-04",{"date":251,"type":37},"2022-05-05",{"date":253,"type":37},"2021-03-11",{"date":255,"type":22},"2031-03-10",{"name":257,"class":44},"Cliniques universitaires Saint-Luc- Université Catholique de Louvain",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":267,"conditions":268,"keywords":269,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":45},"100432072","canadian-scad-study-100432072","NCT04906356","Canadian SCAD Study","Canadian Spontaneous Coronary Artery Dissection (SCAD) Study and Genetic Sub-study (Prospective, Observational Registry With 10 Year Follow-up)","Inclusion Criteria:\n\n1. Patients admitted with ACS (STEMI, NSTEMI or unstable angina)\n2. Documented SCAD on a coronary angiogram (including diagnosis with OCT or IVUS)\n\nExclusion Criteria:\n\n1\\. Patients where SCAD is attributed to atherosclerotic coronary artery disease, with atherosclerotic coronary artery disease stenosis ≥50%",{"count":266,"type":22},3000,"Natural history multicenter, prospective, observational registry with 10-year follow-up",[27,61,26],[270,271,272,273,274,61,27],"Fibromuscular displasia (FMD)","Myocardial Infarction","Myocardial Infarction in women","Non-atherosclerotic coronary artery disease (NACAD)","Myocardial Infarction with no obstructive coronary artery disease (MINOCA)","2021-05-25",{"date":277,"type":37},"2021-05-28",{"date":279,"type":37},"2018-12-01",{"date":281,"type":22},"2033-12-01",{"name":283,"class":44},"Cardiology Research UBC"]